Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aequus Pharmaceuticals Inc (AQS.VN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX-V]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX-V]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 27,470
  • Shares Outstanding, K 71,351
  • Annual Sales, $ N/A
  • Annual Income, $ N/A
  • 36-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.82
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.07
  • Most Recent Earnings -0.01 on 09/30/17
  • Next Earnings Date 12/05/17
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.210 +83.33%
on 12/20/17
0.450 -14.44%
on 01/11/18
+0.165 (+75.00%)
since 12/15/17
3-Month
0.150 +156.67%
on 11/21/17
0.450 -14.44%
on 01/11/18
+0.185 (+92.50%)
since 10/16/17
52-Week
0.135 +185.19%
on 09/08/17
0.480 -19.79%
on 03/02/17
+0.110 (+40.00%)
since 01/16/17

Most Recent Stories

More News
Aequus Announces Proposed $300,000 Equity Financing

VANCOUVER, BC--(Marketwired - January 11, 2018) -

AQS.VN : 0.385 (+1.32%)
AQSZF : 0.3139 (+2.38%)
CannaRoyalty and Aequus Pharmaceuticals Announce Joint Venture to Develop and Commercialize Cannabis-Based Therapies Targeting Neurological Disorders

CannaRoyalty to contribute Bodhi Research position into the JV in exchange for equity

CNNRF : 3.4700 (+3.58%)
AQS.VN : 0.385 (+1.32%)
AQSZF : 0.3139 (+2.38%)
CRZ.CN : 4.330 (+2.36%)
CannaRoyalty and Aequus Pharmaceuticals Announce Joint Venture to Develop and Commercialize Cannabis-Based Therapies Targeting Neurological Disorders

CannaRoyalty to contribute Bodhi Research position into the JV in exchange for equity

CNNRF : 3.4700 (+3.58%)
AQSZF : 0.3139 (+2.38%)
AQS.VN : 0.385 (+1.32%)
Aequus Provides Third Quarter 2017 Operational Highlights

VANCOUVER, BC--(Marketwired - November 29, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.385 (+1.32%)
AQSZF : 0.3139 (+2.38%)
Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole

Continues to build patent portfolio and strengthen protection for antipsychotic transdermal program following completion of proof of concept clinical trials

AQS.VN : 0.385 (+1.32%)
AQSZF : 0.3139 (+2.38%)
Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole

Continues to build patent portfolio and strengthen protection for antipsychotic transdermal program following completion of proof of concept clinical trials

AQS.VN : 0.385 (+1.32%)
AQSZF : 0.3139 (+2.38%)
Ehave Highlights Recent Developments and Corporate Strategy in Updated Letter to Shareholders

Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced publication of a new CEO letter to the Company's...

AQS.VN : 0.385 (+1.32%)
LEAF.TO : 23.40 (-1.22%)
EHVVF : 0.0850 (+21.43%)
Ehave Highlights Recent Developments and Corporate Strategy in Updated Letter to Shareholders

Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced publication of a new CEO letter to the Company's...

AQS.VN : 0.385 (+1.32%)
LEAF.TO : 23.40 (-1.22%)
EHVVF : 0.0850 (+21.43%)
Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch

VANCOUVER, BC--(Marketwired - September 07, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.385 (+1.32%)
AQSZF : 0.3139 (+2.38%)
Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch

VANCOUVER, BC--(Marketwired - September 07, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.385 (+1.32%)
AQSZF : 0.3139 (+2.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Key Turning Points

2nd Resistance Point 0.408
1st Resistance Point 0.397
Last Price 0.385
1st Support Level 0.372
2nd Support Level 0.358

See More

52-Week High 0.480
Last Price 0.385
Fibonacci 61.8% 0.348
Fibonacci 50% 0.307
Fibonacci 38.2% 0.267
52-Week Low 0.135

See More

Business Summary

Aequus Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in developing and commercializing differentiated products.

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.